Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatol Pract Concept [Internet]. 2024 Oct. 30 [cited 2024 Dec. 5];14(4):e2024284. Available from: https://dpcj.org/index.php/dpc/article/view/4769